[go: up one dir, main page]

ES2670668T3 - Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica - Google Patents

Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica Download PDF

Info

Publication number
ES2670668T3
ES2670668T3 ES13798222.9T ES13798222T ES2670668T3 ES 2670668 T3 ES2670668 T3 ES 2670668T3 ES 13798222 T ES13798222 T ES 13798222T ES 2670668 T3 ES2670668 T3 ES 2670668T3
Authority
ES
Spain
Prior art keywords
masp
treatment
paroxysmal nocturnal
nocturnal hemoglobinuria
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13798222.9T
Other languages
English (en)
Inventor
Hans-Wilhelm Schwaeble
Gregory A. Demopulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Application granted granted Critical
Publication of ES2670668T3 publication Critical patent/ES2670668T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)

Abstract

Una composición que comprende una cantidad de un agente inhibidor de la MASP-3, eficaz para inhibir la activación del complemento dependiente de la MASP-3, para usar en el tratamiento de un sujeto que padece de hemoglobinuria paroxística nocturna (HPN), en la que dicho agente inhibidor de la MASP-3 es un anticuerpo monoclonal de la MASP-3 o un fragmento del mismo que se une específicamente a una porción de la MASP-3humana (ID. DE SEC. N.º 8).
ES13798222.9T 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica Active ES2670668T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06
US201261621461P 2012-04-06
PCT/US2013/035488 WO2013180834A2 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
ES2670668T3 true ES2670668T3 (es) 2018-05-31

Family

ID=49325295

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13798222.9T Active ES2670668T3 (es) 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica
ES18158799T Active ES2894944T3 (es) 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-2 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18158799T Active ES2894944T3 (es) 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-2 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica

Country Status (29)

Country Link
US (3) US20130273053A1 (es)
EP (2) EP3366307B1 (es)
JP (3) JP6366571B2 (es)
KR (2) KR102142508B1 (es)
CN (1) CN104661676A (es)
AU (3) AU2013267909B2 (es)
BR (1) BR112014024793A2 (es)
CA (2) CA3087933A1 (es)
CL (1) CL2014002694A1 (es)
CY (1) CY1120736T1 (es)
DK (2) DK3366307T3 (es)
ES (2) ES2670668T3 (es)
HR (1) HRP20180671T1 (es)
HU (1) HUE036930T2 (es)
IL (2) IL234991B (es)
IN (1) IN2014KN02324A (es)
LT (1) LT2833907T (es)
MX (2) MX388278B (es)
NO (1) NO2881536T3 (es)
NZ (2) NZ629675A (es)
PL (2) PL3366307T3 (es)
PT (1) PT2833907T (es)
RS (1) RS57266B1 (es)
RU (2) RU2655299C2 (es)
SI (1) SI2833907T1 (es)
SM (1) SMT201800253T1 (es)
TR (1) TR201806939T4 (es)
WO (1) WO2013180834A2 (es)
ZA (1) ZA201408100B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60541B1 (sr) * 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
LT2861246T (lt) * 2012-06-18 2021-04-26 Omeros Corporation Masp-1 ir (arba) masp-2, ir (arba) masp-3 slopinimo kompozicijos ir būdai, skirti įvairių ligų ir sutrikimų gydymui
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ629682A (en) 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
TWI776827B (zh) 2016-11-28 2022-09-11 日商中外製藥股份有限公司 能夠調節配體結合活性的配體結合分子
KR102630923B1 (ko) * 2016-11-28 2024-01-30 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
EP3606965A4 (en) 2017-04-03 2021-01-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MASP-1 ANTIBODIES AND METHODS OF USE
WO2019107380A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
CN112867706B (zh) 2018-05-29 2024-11-15 奥默罗斯公司 Masp-2抑制剂和使用方法
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
PH12022550149A1 (en) * 2019-07-31 2022-11-21 Biocryst Pharm Inc Dosing regimens for oral complement factor d inhibitors
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
CN115103709A (zh) 2019-12-04 2022-09-23 奥默罗斯公司 Masp-2抑制剂和使用方法
CN115052604A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
EP4199954A4 (en) 2020-08-18 2024-12-25 Omeros Corporation Monoclonal antibodies, compositions and methods for detecting complement factor d
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器
MX2024007065A (es) * 2021-12-10 2024-06-20 Omeros Corp Anticuerpos terapeuticos que se unen al dominio de serina proteasa de masp-2 y sus usos.
WO2024251199A1 (zh) * 2023-06-09 2024-12-12 舒泰神（北京）生物制药股份有限公司 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
RU2002113381A (ru) * 1999-12-02 2004-01-27 Дженс Христиан ДЖЕНСЕНИУС (DK) MASP-3, комплемент-связывающий фермент и его применение
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
CA2515453C (en) * 2003-02-21 2013-09-24 Tanox, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20070253949A1 (en) * 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
DE602006004582D1 (de) * 2006-07-31 2009-02-12 Fiat Ricerche Durch eine Fluidströmung betätigbarer elektrischer Generator
US8679845B2 (en) 2007-05-31 2014-03-25 University Of Washington B cells modified to reversibly induce accelerated mutagenesis of target genes
AU2009296297A1 (en) * 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
WO2010102247A2 (en) * 2009-03-05 2010-09-10 Smith & Nephew, Inc. System, method, and apparatus for locating a femoral neck guide wire
CA2767755C (en) * 2009-07-17 2021-10-12 Rigshospitalet Inhibitors of complement activation
CN102958535A (zh) * 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
KR102217658B1 (ko) 2011-04-08 2021-02-22 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법

Also Published As

Publication number Publication date
WO2013180834A3 (en) 2014-04-03
CY1120736T1 (el) 2019-12-11
CA3087933A1 (en) 2013-12-05
NZ781091A (en) 2022-04-29
RU2018114903A3 (es) 2021-08-12
SI2833907T1 (en) 2018-07-31
AU2013267909B2 (en) 2018-03-01
EP2833907A2 (en) 2015-02-11
CA2869326C (en) 2021-09-21
US20220242972A1 (en) 2022-08-04
IL234991B (en) 2020-06-30
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
PL2833907T3 (pl) 2018-08-31
KR20200097808A (ko) 2020-08-19
EP2833907B1 (en) 2018-02-28
NO2881536T3 (es) 2018-06-30
KR102142508B1 (ko) 2020-08-10
RU2014144621A (ru) 2016-05-27
IL234991A0 (en) 2014-12-31
JP2015514117A (ja) 2015-05-18
HUE036930T2 (hu) 2018-08-28
RS57266B1 (sr) 2018-08-31
NZ727063A (en) 2021-10-29
HK1206996A1 (en) 2016-01-22
IL274721B (en) 2022-04-01
MX357540B (es) 2018-07-13
KR102318623B1 (ko) 2021-11-02
JP6815355B2 (ja) 2021-01-20
PT2833907T (pt) 2018-05-29
JP2021001199A (ja) 2021-01-07
DK2833907T3 (en) 2018-05-28
DK3366307T3 (da) 2021-11-01
AU2018200721B2 (en) 2020-03-26
CN104661676A (zh) 2015-05-27
RU2655299C2 (ru) 2018-05-24
SMT201800253T1 (it) 2018-07-17
MX388278B (es) 2025-03-18
AU2018200721A1 (en) 2018-02-22
US20190382505A1 (en) 2019-12-19
BR112014024793A2 (pt) 2019-08-27
IL274721A (en) 2020-07-30
MX2018008658A (es) 2021-10-19
US20130273053A1 (en) 2013-10-17
RU2018114903A (ru) 2019-03-04
NZ629675A (en) 2017-02-24
AU2020204163A1 (en) 2020-07-09
AU2013267909A1 (en) 2014-11-27
JP2018162307A (ja) 2018-10-18
LT2833907T (lt) 2018-06-11
EP3366307A1 (en) 2018-08-29
KR20150003785A (ko) 2015-01-09
CA2869326A1 (en) 2013-12-05
WO2013180834A2 (en) 2013-12-05
ZA201408100B (en) 2022-05-25
CL2014002694A1 (es) 2015-08-28
JP6366571B2 (ja) 2018-08-01
ES2894944T3 (es) 2022-02-16
IN2014KN02324A (es) 2015-05-01
PL3366307T3 (pl) 2022-03-07
HRP20180671T1 (hr) 2018-07-13
EP2833907A4 (en) 2016-03-16
EP3366307B1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
ES2670668T3 (es) Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
ES2683307T3 (es) Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
NZ745531A (en) Methods for inhibiting angiogenesis in a subject in need thereof
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
UA109658C2 (xx) Антитіло проти cgrp
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
MX2013003076A (es) Terapeuticos contra cancer de mama.
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
MX2019009122A (es) ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).
AR101740A1 (es) Terapia de combinación y composiciones
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
BR112018072681A2 (pt) anticorpos anti-il-1r3 humanizados
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
EA201990298A1 (ru) Способы и композиции для лечения рака